Navigation Links
Abaxis Launches The VetScan(R) HM5 a State-of-the-Art 5-Part Differential Veterinary Hematology Analyzer
Date:9/17/2007

UNION CITY, Calif., Sept. 17 /PRNewswire-FirstCall/ -- Abaxis, Inc. (Nasdaq: ABAX), a medical products company manufacturing point-of-care blood analysis systems for both the medical and veterinary markets, introduced today the VetScan HM5, a fully-automated 5-part differential cell counter specifically designed for veterinary applications. The VetScan HM5 provides a comprehensive 22-parameter complete blood count with cellular histograms in just minutes for cat, dog and horse, and offers a 3-part mode for seven other species.

The versatile VetScan HM5 incorporates superior performance, ease of use, offers true database management and minimal maintenance making it an attractive alternative for veterinary clinics, research laboratories, and pharmaceutical/biotech companies either using a commercial lab or in house hematology instruments. Other advantages over competitive in house instruments include a 20% lower operating cost, a 50% smaller sample size and 40% faster time to results.

"The VetScan HM5 provides veterinary practices the ability to arrive at more timely diagnoses and treatment plans that can improve patient outcomes and quality of life," said Larry Lem, Abaxis Hematology Product Manager. "With its well-documented accuracy, dependable reproducibility, ease of use and its significant cost savings as compared to the commercial lab, the VetScan HM5 will become an essential tool in improving the efficiency of veterinary practices across the globe.

The new VetScan HM5 requires seconds of hands-on time to perform complete blood count (CBC) measurements on 10 available species. The operator enters the appropriate patient information, inserts a well-mixed blood sample and presses the "start" button. In just two minutes, test results and four cellular histograms will be displayed, permitting the veterinarian to complete a routine annual check-up, and/or make a timely diagnosis and devise an appropriate treatment plan.

Martin Mulroy, Vice President Marketing and Sales for the Veterinary business added, "We have significantly ramped up both our field sales team and inside sales group in anticipation of this product release in order to better meet the expected demand. Abaxis now offers the marketplace a choice in hematology instruments, the VetScan HM2 and VetScan HM5, and is poised to compete on multiple levels. This product line extension will also allow for increased complete system placements, increasing demand and sales of the Abaxis VetScan VS2 chemistry, electrolytes and immunoassay system and the associated rotors."

About Abaxis, Inc.

Abaxis develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer. The veterinary business also provides to the veterinarian and research market now a line of hematology instruments for point of care complete blood counts (CBC).

This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. Specific forward-looking statements contained in this press release include, but are not limited to, risks and uncertainties related to the market acceptance of the Company's products and the continuing development of its products, risks associated with manufacturing and distributing its products on a commercial scale, risks associated with entering the human diagnostic market on a larger scale, risks involved in carrying of inventory, risks from unexpected problems or delays in the Company's manufacturing facility, risks associated with the ability to attract and retain competent sales personnel, general market conditions, competition, risks and uncertainties related to its ability to raise capital in order to fund its operations and other risks detailed from time to time in Abaxis' periodic reports filed with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statement was made. Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.

Contact: Clint Severson Lytham Partners, LLC

Chief Executive Officer Joe Dorame, Robert Blum and Joe Diaz

Abaxis, Inc. 602-889-9700

510-675-6500


'/>"/>
SOURCE Abaxis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Glaxo launches pills to help smokers quit in 7-12 weeks
2. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
3. Dr Reddy’s Laboratories launches Hyalosy
4. Serum Institute Launches New Tetanus-Diphtheria Vaccine
5. Scottish Health Minister Launches Organ Donor Plan
6. GlaxoSmithKline launches diabetes and cancer drugs
7. Ranbaxy Launches Once-a-day Inhaler For Asthma Patients
8. Pfizer Launches Viagra For Lung Disease In UK
9. PM Launches Healthcare Foundation For India
10. African Union Launches A Programme On Acceleration of HIV Prevention
11. Yale School of Medicine Launches Telemonitoring Of Heart Failure Symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: a dauntless ... interrelate. “End Time GPS” is the creation of published author, Wesley Gerboth, a ... on military munitions and space-vehicle projects. Now, at age ninety-one, he shares the Wisdom ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion of ... people of God in congregations across the United States. “The Communion of ... in 1964 who has served congregations in seven states throughout his long career ...
(Date:3/23/2017)... & Seattle, WA (PRWEB) , ... March 23, 2017 , ... ... health emergency and now estimates that there could be four million Zika-related cases in ... epidemics to date with numbers of US cases reported per year skyrocketing to an ...
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF Orthopaedic Center PA ... Area. The new location is located at 2255 E. Mossy Oaks Rd., Suite 440, ... newest location will provide patients living in the north Houston area (The Woodlands, Conroe, ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy ... 960 Gruene Road in Building 2. The clinic is the group’s second in New ... says opening the company’s second New Braunfels location brings things full circle for the ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... March 24, 2017 FinancialBuzz.com News Commentary  ... According ... of cannabis market research, the legal cannabis market is projected ... 2021, despite conflicting signals from the current presidential administration. The ... the two biggest drivers of growth in this industry are ...
(Date:3/24/2017)... DUBLIN , Mar 24, 2017 Research ... in Drug Discovery and Diagnostics, 2017 - 2035" report to ... The ... current landscape and future outlook of the growing market of deep ... data revolution, deep learning algorithms have emerged as a novel solution ...
(Date:3/24/2017)... NEW YORK , March 24, 2017 ... Appliances and Equipment stocks, which are: Neovasc Inc. (NASDAQ: NVCN), ... Sunshine Heart Inc. (NASDAQ: SSH ). These companies ... of its prior gains on Thursday, March 23 rd , ... the afternoon, while shares of health care companies in the ...
Breaking Medicine Technology: